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Abstract
OBJECTIVE—There are two major sources of cholinergic projections in the brain. The nucleus
basalis of Meynert provides the principal cholinergic input of the cortical mantle and the
pedunculopontine nucleus-laterodorsal tegmental complex (PPN-LDTC; hereafter referred to as
PPN) provides the major cholinergic input to the thalamus. Cortical cholinergic denervation has
previously been shown to be part of Alzheimer and parkinsonian dementia but there is less
information about subcortical thalamic cholinergic denervation. We investigated thalamic
cholinergic afferent integrity by measuring PPN-Thalamic (PPN-Thal) acetylcholinesterase
(AChE) activity via PET imaging in Alzheimer (AD), Parkinson disease without dementia (PD),
Parkinson disease with dementia (PDD) and dementia with Lewy bodies (DLB).
METHODS—AD (n=13; mean age 75.4±5.5), PD (n=11; age 71.4±6.4), PDD (n=6; age
70.8±4.7), DLB (n=6; age 68.0±8.6) and normal controls (NC; n=14; age 69.0±7.5) subjects
underwent AChE [11C]-methyl-4-piperidinyl propionate (PMP) PET imaging. PPN-Thal PET data
were analyzed using the Nagatsuka method.
RESULTS—There were no significant differences in mean age between the groups (F=1.86,
p=0.134). Kruskal-Wallis testing demonstrated a significant group effect for PPN-Thal AChE
hydrolysis rates (F=9.62, P<0.0001). Compared to NC, reduced thalamic k3 hydrolysis rate was
noted in subjects with PDD (−19.8%; AChE k3 hydrolysis rates 0.1072±0.0143 min−1), DLB
(−17.4%; 0.1103±0.0112 min−1) and PD (−12.8%; 0.1165±0.0114 min−1). Each of these 3
subgroups were statistically different from AD subjects (−0.7%; 0.1326±0.0095 min−1) who
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showed relatively spared thalamic k3 hydrolysis rates which were comparable to NC
(0.1336±0.0142 min−1).
CONCLUSIONS—Thalamic cholinergic denervation is present in PD, PDD, and DLB but not in
AD. Neurodegenerative involvement of thalamic cholinergic afferent projections may contribute
to disease-specific motor and cognitive abnormalities.
Keywords
Acetylcholine; [11C] PMP PET; Alzheimer disease; Parkinson disease; PPN; Parkinson disease
with dementia
Introduction
Cortical cholinergic denervation is a well-established pathological hallmark of Alzheimer
disease (AD).[7] The two principle cholinergic projection systems of the brain include the
basal forebrain system, in particular the nucleus basalis of Meynert (nBM), which supplies
cholinergic projections throughout the cerebral cortex and pontine projection system,
including the pedunculopontine nucleus (PPN) and the lateral dorsal tegmental nucleus
(LDTN), both of which provide cholinergic innervation to various subcortical structures
including the basal ganglia, thalamus, brainstem and rostral spinal cord.[10, 20] While loss
of nBM cholinergic neurons is a classic feature of feature of AD[26], less is known about
the integrity of the pontine cholinergic projection system and its role in the pathogenesis of
AD.
Though cortical cholinergic changes are recognized as a universal hallmark of late-stage
AD, we have previously reported in vivo imaging findings suggesting that cortical
cholinergic deficits in mild to moderate AD are less robust in comparison to those seen in
Parkinson disease (PD) with dementia (PDD) of comparable severity of dementia.[4]
Interestingly, thalamic cholinergic changes have also been described in PD without
dementia and may associate with a propensity for falls and REM sleep behavior disorder.[5,
15] As the presence of REM sleep behavior disorder and falls is much more common in PD
than in AD, it is possible that these clinical phenotypic differences between these
neurodegenerative disorders may reflect differences in the integrity of the cholinergic
system.
In vivo [11C]-methyl-4-piperidinyl propionate (PMP) positron emission tomography (PET)
imaging assessment of acetylcholinesterase (AChE) activity in the human brain is a reliable
marker for cholinergic terminal integrity[24] and also allows the differential assessment of
cortical and subcortical (PPN-Thal) cholinergic systems in vivo. We performed [11C]-PMP
PET imaging in subjects with AD and various alpha-synuclein-related disorders (PD, PDD,
and Dementia with Lewy Bodies--DLB) to assess the possible differential role of the pontine
cholinergic projection system in these neurodegenerative diseases. We hypothesized that
thalamic cholinergic denervation is present in these parkinsonian disorders but not in AD.
Methods
Subjects
This study involved 50 subjects: 13 with AD, 11 with PD, 6 with PDD, 6 with DLB, and 14
normal controls (NC). Results of the cortical AChE data from these subjects has been
published previously.[4] There were no significant differences in mean (SD) age among the
groups (table 1): those with AD, 75.4 (5.5) years; those with PD, 71.4 (6.4) years; those with
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PDD, 70.8 (4.7) years; those with DLB, 68.0 (8.6) and NCs, 69.0 (7.5) years; F = 1.86, P =
0.134).
Mini-Mental State Examination (MMSE) scores (mean [SD]) were decreased in the groups
with dementia with those with AD being 22.1 (5.0); those with PD, 27.2 (2.6); those with
PDD, 23.8 (2.6); those with DLB 21.3 (6.7); and NCs, 29.0 (1.6); (F = 8.15, P<.001) but the
scoreswere not significantly different between the AD group and PDD/DLB-affected groups
(t = −0.25, P = 0.80). MMSE scores were not significantly different between those who had
PDD and those who had DLB (mean [SD], 23.8 [2.6] and 21.3 [6.6], respectively; t = 0.86, P
= 0.41). Gender distribution was different among groups: AD (8 women, 4 men); PD (0
women, 11 men); PDD (0 women, 6 men); DLB (1 woman, 5 men); NC (4 women, 10
men). The overrepresentation of males in our cohort may reflect both the increased
prevalence of Parkinson disease amongst men[3] as well as the relatively male-predominant
gender demographics of subjects recruited from the Veteran Affairs Healthcare system.
However, previous AChE PET studies in NC did not find AChE-activity gender differences
in either cortical or thalamic regions of interest.[16]
AD subjects were diagnosed using the NINCDS-ADRDA (National Institute of
Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related
Disorders Association) criteria.[2, 18] PDD was diagnosed in patients having a history of
idiopathic PD with incident dementia. DLB was clinically diagnosed following the
Consortium on Dementia With Lewy Bodies' criteria.[17] No subjects were taking
anticholinergic or cholinesterase inhibitor drugs. Subjects with PD, PDD, and DLB were
taking a variable combination of carbidopa-levodopa, selegiline hydrochloride, or dopamine
agonists. Dopaminergic medications were withheld for at least 12 to 18 hours (overnight
withdrawal) prior to PET imaging the next morning. All NC subjects had a normal
neurological examination at the time of the study. This study was approved by the
institutional review board and informed consent was obtained for all subjects.
AChE PET AND MAGNETIC RESONANCE IMAGING
The [11C]PMP radioligand is an acetylcholine analogue that serves as a selective substrate
for AChE hydrolysis.[11] The hydrolyzed radioligand becomes trapped as a hydrophilic
product locally in the brain following the AChE biodistribution. The [11C]PMP was
prepared using a previously described method[25]. Dynamic PET scanning was performed
for 80 minutes following a bolus intravenous injection of 15 mCi (555 MBq) of [11C]PMP.
Sequential emission scans were obtained in 3-dimensional imaging mode using an emission
computed axial tomograph (ECAT HR+; CTI PET Systems, Knoxville, Tenn), which
acquires 63 transaxial slices (slice thickness, 2.4 mm with an in-plane resolution of 4.1 mm).
A thermoplastic mask was made for each subject to minimize head movement. The PET
emission data were corrected for attenuation, scatter, and radioactive decay.
A volumetric spoiled–echo gradient recall MRI was collected for each subject using a 1.5-T
scanner (Signa; GE Medical Systems, Milwaukee, Wis). The MRI data were cropped in
preparation for alignment with the PET data using AnalyzeAVW software (Biomedical
Imaging Resource; Mayo Foundation, Rochester, Minn).
DATA ANALYSIS
All dynamic PET image frames were spatially co-registered within subjects with a rigid-
body transformation to reduce the effects of subject motion during the imaging session [22].
Data were co-registered, reoriented, and nonlinearly warped using NeuroStat routines.
Thalamic volume-of-interest was determined using an in-house developed brain PET atlas.
[21, 22]
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AChE hydrolysis rates (k3) were estimated using a method using the striatum as the
reference input tissue.[23] Mean right & left thalamic AChE hydrolysis rates were averaged.
The Kruskal-Wallis test and post-hoc Wilcoxon rank-sum testing with Bonferonni
correction for multiple comparisons were used for statistical group comparison.
Results
Mean thalamic AChE Activity [11C]PMP k3 values for all subgroups are shown in table 2.
Kruskal-Wallis testing revealed significant differences between subgroups (χ2 =24.03, p <
0.001). AD subjects showed relatively preserved thalamic cholinergic innervations
compared to subjects with PD, PDD and DLB. Relative to NCs, AD subjects showed only a
0.7% reduction in thalamic k3 hydrolysis rate. Comparatively, subjects with PD (12.8%),
PDD (19.8%), and DLB (17.4%) showed significantly greater thalamic cholinergic
denervation relative to both AD and NCs (Figure 1). Figure 2 depicts subgroup averages for
regional mean PMP k3.
Intergroup comparisons were performed using the Wilcoxon rank-sum test with Bonferonni
correction (Significant p-value defined as < 0.008). Differences in thalamic [11C] PMP k3
were seen between AD subjects and subjects with PD (Z= −3.071, p = 0.002), PDD (Z=
−2.982, p = 0.003) and DLB (Z=−2.982, p=0.003) (table 3). There were no significant
differences between AD subjects and NCs (Z = −0.34, p = 0.734). Subjects with PDD
showed the lowest PMP thalamic hydrolysis rate amongst all subgroups though Wilcoxon
rank-sum test did not demonstrate a statistically significant difference between PDD and
DLB groups (Z = −0.641, p = 0.522). There were no significant differences between the PD
versus the PDD/DLB groups (Z = 1.385, p = 0.166).
Discussion
Our in vivo imaging findings suggest that patients with mild AD have similar thalamic
cholinergic system integrity compared to normal controls and no significant thalamic
cholinergic denervation compared to PD and parkinsonian dementia patients. These findings
are consistent with the limited published post-mortem literature on the pontine cholinergic
system in AD. Dugger et al. compared postmortem PPN/LDTN findings in subjects with
Lewy-body-related disorders (LBD) (n=19), AD (n=19) and normal controls (n =10) and
found the PPN and LDTN to be susceptible to Lewy body pathology in LBD and tau
pathology in AD. However, only the subjects with Lewy body disorders were found to have
significant cell loss relative to normal controls.[8] Woolf et al. found similar results in a
smaller postmortem study involving 4 subjects with AD.[27] Brandel et al. found selective
loss of subtantia innominata neurons in AD whereas there was sparing of the brainstem
cholinergic neurons.[6]
In animal models of neurodegenerative disorders, impairment of the pontine cholinergic
projection system has been associated with a number of motor and non-motor features
including sleep disorders and gait imbalance. Janzen et al. recently demonstrated an
association between visual hallucinations in PD and PPN atrophy as assessed by voxel based
morphometry.[13] We have recently found an association between symptoms of REM sleep
behavior disorder in PD and both cortical and thalamic subcortical cholinergic denervation.
[15] We also previously reported on higher incidence of falls in PD related to PPN/Thal
cholinergic denervation.[5] As both RBD and falls are not common symptoms in
prototypical AD these clinical phenotypic features may reflect thalamic cholinergic
denervation. PPN/LDTN cholinergic denervation may also portend the development of a
specific cognitive subtype more analogous to the frontal-subcortical cognitive syndrome
seen in early PD that tends to manifest with impaired attention, executive dysfunction, and
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to a lesser extent, visuospatial impairment.[14] This cognitive phenotype may be associated
with postural instability and gait difficulties in PD and may auger increased risk of
dementia.[1, 12]
In contrast to the degeneration of the basal forebrain complex in AD, the cholinergic
innervation of the striatum (mainly originating from striatal interneurons) and of the
thalamus (mainly originating from the brainstem) appears to remain relatively intact.[19]
Hence, AD may be best characterized not by general cholinergic neuronal loss but rather by
selective cholinergic denervation of the cerebral cortex, most severely in the temporal lobes
and in the adjacent paralimbic areas.[9]
Our findings lend credence to the association between alpha-synucleinopathies and
subcortical cholinergic dennervation, though they do not provide support for the early
involvement of the pontine cholinergic system in AD. Differences in the integrity of
subcortical cholinergic networks may reflect differential cell-specific vulnerability to alpha-
synuclein aggregates vs tau. A limitation of our study is our relatively small sample sizes
and skewed gender distriubtion of DLB and PDD subjects. A limitation of the PMP
radioligand is that it is not a good tracer to assess striatal AChE activity. We also note that
the lack of an assocation in our cross-sectional study does not rule out the possibility of later
involvement of the PPN/LDTN in more advanced AD.
Conclusion
Our findings suggest that the pontine cholinergic projection system may be relatively spared
in early AD. Ongoing advances in the functional neuroimaging may allow for further
correlative analyses amongst neurodegenerative diseases with shared cognitive symptoms.
Highlights
The forebrain and subcortical systems are the principle brain cholinergic projection
systems
AChE [11C]-(PMP) PET estimates in vivo integrity of cholinergic terminals
Subcortical cholinergic denervation is relatively spared in Alzheimer disease compared to
parkinsonian disorders




LDTC laterodorsal tegmental complex
PET positron emission tomography
[11C]PMP AChE [11C]-methyl-4-piperidinyl propionate
AD Alzheimer disease
PD Parkinson disease
PDD Parkinson Disease with Dementia
DLB Dementia with Lewy Bodies
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Relative (% difference) subcortical cholinergic denervation in Alzheimer disease and alpha-
synucleinopathies compared to healthy controls.
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Legend: (AD)= Alzheimer disease, (PD) = Parkinson disease, (PDD) = Parkinson Disease
with Dementia, (DLB) = Dementia with Lewy Bodies
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Table 1
Demographic information
AD (n=13) PD (n=11) PDD (n=6) DLB (n=6) NC (n=14)
Age (SD) 75.4 (5.5) 71.4 (6.4) 70.8 (4.7) 68.0 (8.6) 69.0 (7.5)
MMSE (SD) 22.1 (5.0) 27.2 (2.6) 23.8 (2.6) 21.3 (6.7) 29.0 (1.6)
Gender (F/M) (8/4) (0/11) (0/6) (1/5) (4/10)
MMSE = Mini-mental State Exam, SD = Standard Deviation (AD)= Alzheimer disease, (PD) = Parkinson disease, (PDD) = Parkinson Disease
with Dementia, (DLB) = Dementia with Lewy Bodies
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Table 3
Wilcoxon Rank-Sum test comparing [11C]PMP k3 hydrolysis rates (min−1) in Alzheimer disease compared to
other neurodegenerative disorders and normal controls
Wilcoxon Rank-Sum test
AD vs NC z =−0.340 , p = 0.734
AD vs DLB z =−2.982 , p = 0.003*
AD vs PD z =−3.071 , p = 0.002*
AD vs PDD z =−2.982 , p = 0.003*
(AD)= Alzheimer disease, (PD) = Parkinson disease, (PDD) = Parkinson Disease with Dementia, (DLB) = Dementia with Lewy Bodies, , (NC) =
Normal Controls.
*
Statistically significant. Note: p-value for statistical significance < 0.008 based on Bonferonni correction for multiple comparisons
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